266
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera

, , , , , , , & show all
Pages 2479-2486 | Received 17 Mar 2012, Accepted 21 May 2012, Published online: 09 Jul 2012

References

  • Baxter EJ, Scott LM, Campbell PJ, . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
  • James C, Ugo V, Le Couedic JP, . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
  • Kralovics R, Passamonti F, Buser AS, . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
  • Levine RL, Wadleigh M, Cools J, . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–397.
  • Cleyrat C, Jelinek J, Girodon F, . JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia 2010;24:1069–1073.
  • Kratz CP, Boll S, Kontny U, . Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006;20:381–383.
  • Scott LM, Tong W, Levine RL, . JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459–468.
  • Tefferi A, Thiele J, Orazi A, . Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097.
  • Lippert E, Girodon F, Hammond E, . Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009;94:38–45.
  • Carillo S, Henry L, Lippert E, . Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of jak2 exon 12 mutations-clinical relevance in the monitoring of polycythemia. J Mol Diagn 2011;13:263–270.
  • Er TK, Lin SF, Chang JG, . Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. Clin Chim Acta 2009;408:39–44.
  • Qian J, Lin J, Yao DM, . Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. Clin Chim Acta 2010;411:2097–2100.
  • Rapado I, Grande S, Albizua E, . High resolution melting analysis for JAK2 exon 14 and exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 2009;11:155–161.
  • Ugo V, Tondeur S, Menot ML, . Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS One 2010; 5:e8893.
  • Gundry CN, Dobrowolski SF, Martin YR, . Base-pair neutral homozygotes can be discriminated by calibrated high-resolution melting of small amplicons. Nucleic Acids Res 2008;36:3401–3408.
  • Dwight Z, Palais R, Wittwer CT. uMELT: prediction of high-resolution melting curves and dynamic melting profiles of PCR products in a rich web application. Bioinformatics 2011;27:1019–1020.
  • Burjanivova T, Marcinek J, Lasabova Z, . A novel JAK2 exon 12 mutation identified in the retrospective analysis of paraffin-embedded tissues of polycythemia vera patients. Diagn Mol Pathol 2009;18:108–111.
  • Nussenzveig RH, Swierczek SI, Jelinek J, . Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007;35:32–38.
  • Funakoshi-Tago M, Tago K, Sumi K, . The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice. J Biol Chem 2009;284:12680–12690.
  • Murugesan G, Aboudola S, Szpurka H, . Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006;125:625–633.
  • Olsen RJ, Dunphy CH, O’Malley DP, . The implication of identifying JAK2 (V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis. J Hematop 2008;1:111–117.
  • Olsen RJ, Tang Z, Farkas DH, . Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system.. Arch Pathol Lab Med 2006;130: 997–1003.
  • Szpurka H, Tiu R, Murugesan G, . Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006;108:2173–2181.
  • Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011;86:668–676.
  • Funakoshi-Tago M, Pelletier S, Moritake H, . Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 2008;28:1792–1801.
  • Ma W, Kantarjian H, Zhang X, . Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 2009;11:49–53.
  • Reading NS, GC Prchal JT. Rapid and sensitive detection and identification of JAK2 exon 12 mutations in V617F-negative myeloproliferative disorders by polymerase chain reaction. Presented at Association for Molecular Pathology meeting. 2009. Kissimmee, FL.
  • Laughlin TS, Moliterno AR, Stein BL, . Detection of exon 12 mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing. J Mol Diagn 2010;12: 278–282.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.